

Biocon Biologics Limited

CIN: U24119KA2016PLC093936

Biocon House, Tower-3,
Semicon Park Electronic City, Phase - II,
Hosur Road, Bengaluru, Karnataka 560100 IN**T** +91 080-6775 6775, **F** +91 080-6775 1030**E** contact@bioconbiologics.comwww.bioconbiologics.com

May 25, 2025

Singapore Exchange Securities Trading Limited

4 Shenton Way # 02-01

SGX Centre 2 Singapore 068807

Dear Sir/Madam,

Subject: Company Statement

Please find enclosed the company statement titled ***"Biocon Biologics Receives MHRA, UK Approval for YESINTEK®, Biosimilar Ustekinumab"***.

Kindly take the same on record and acknowledge.

Thanking you

Your faithfully

For Biocon Biologics Limited

Akhilesh Nand**Company Secretary**

Membership No. ACS 13669

Address: Biocon House, Semicon Park
Tower 3, Electronic City Phase 2, Hosur Road
Bengaluru, Karnataka

Encl: as above

NOTIFICATION TO STOCK EXCHANGE

COMPANY STATEMENT

**Biocon Biologics Receives MHRA, UK Approval for YESINTEK®,
Biosimilar Ustekinumab**

Bengaluru, Karnataka, India, May 25, 2025

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisations in the United Kingdom (UK) for YESINTEK®, a biosimilar of Ustekinumab.

YESINTEK® is indicated for the treatment of adults and children from the age of 6 years and older with moderate to severe plaque psoriasis, and adults with active psoriatic arthritis or moderately to severely active Crohn's disease. Clinical data from the trial program demonstrated that our Ustekinumab biosimilar has comparable safety and efficacy to the originator product.

In Europe, the European Commission (EC) recently granted marketing authorisation for Ustekinumab, allowing its commercialization in all European Union (EU) member states and the European Economic Area (EEA).

– Company Spokesperson